LOS ANGELES (Reuters) - Amgen Inc. said on Monday that 48.5 percent of cancer patients not undergoing chemotherapy or radiation who received its anemia drug Aranesp in a clinical trial died compared ...
Amgen Inc.’s anemia treatment Aranesp is safe for use in kidney patients whose disease doesn’t require dialysis, a U.S. panel said Monday. Outside advisers to the Food and Drug Administration said the ...
Shares of Amgen are rallying $1.54, or 4.3 percent, to $37 in pre-open trading after the U.S. Food and Drug Administration approved the biotech firm's Aranesp for the treatment of chemotherapy-induced ...
NEW YORK, Jan 25 (Reuters) - Amgen Inc. on Thursday disclosed negative findings in studies of its Aranesp anemia drug and Vectibix colon cancer treatment, including a higher risk of death among cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results